Virginia Commonwealth University: Lymphoma trials
The registry lists 12 Lymphoma studies with Virginia Commonwealth University as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 6Phase 2 4Phase 3 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
- Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCTCompletedNCT00709592Phase 2Results posted
- CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot TrialCompletedNCT06439420Phase 2
- Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT03964259Phase 1
- Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing TxCompletedNCT03923504Not applicable
- Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLLWithdrawnNCT03639324Phase 1
- Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain TumorsWithdrawnNCT02000986Not applicable
- Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00963274Phase 1
- Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's LymphomaCompletedNCT00005580Phase 1
- Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic LymphomaCompletedNCT00003187Phase 2/3
- Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or LymphomaCompletedNCT00003079Phase 1
- High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic MalignanciesCompletedNCT00002818Phase 1